+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-09-01Number of Pages: 74

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.  

Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs. 

Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy. 

Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE.

global-pipeline-analysis-hospital-acquired-pneumonia-drugs-market

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Secondary Research
      1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions

Chapter 2 Executive Summary
2.1.1 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)

Chapter 3 Market overview
3.1 Introduction
      3.1.1 Types of Nosocomial Pneumonia
               3.1.1.1 Bacterial pneumonia
               3.1.1.2 Viral pneumonia
      3.1.2 Epidemiology of hospital acquired pneumonia
      3.1.3 Diagnosis of hospital acquired pneumonia
      3.1.4 Treatment of hospital acquired pneumonia
3.2 Market Dynamics
      3.2.1 Market Drivers
              3.2.1.1 Rising drug resistance among infectious microorganisms increasing chances of hospital acquired infections
              3.2.1.2 Inefficient sterilization and unhygienic conditions in low and middle income countries increasing prevalence of hospital acquired infections
                         3.2.1.2.1 Prevalence of hospital acquired infections in developed and developing countries
      3.2.2 Market Restraints
              3.2.2.1 Government scrutinizing hospital policies to curb hospital-acquired infections
      3.2.3 Market Opportunities
              3.2.3.1 Promising future for vaccines in the nosocomial pneumonia market
              3.2.3.2 Potential for research in vaccine development for causative agents other than S. pneumonia
3.3 Event Impact Analysis
      3.3.1 Event Impact Analysis: Hospital Acquired Pneumonia Market
3.4 Value Chain Analysis
      3.4.1 Value Chain Analysis
3.5 Porter’s Five Forces Analysis for the Global Hospital Acquired Pneumonia Drugs Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Porter’s Five Forces Analysis: Global Hospital Acquired Pneumonia Market
      3.5.3 Bargaining Power of Buyers
      3.5.4 Threat of Substitutes
      3.5.5 Threat of New Entrants
      3.5.6 Competitive Rivalry
3.6 Market Analysis of Major Drugs and Vaccines for Hospital Acquired Pneumonia
      3.6.1 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)

Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis
4.1 Introduction
4.2 Late Stage (Phase III)
      4.2.1 Tedizolid phosphate
               4.2.1.1 Global Tedizolid Phosphate Market Revenue, 2017 – 2020 (USD million)
      4.2.2 Ceftolozane/Tazobactam
              4.2.2.1 Global Ceftolozane/Tazobactam Market Revenue, 2017 – 2020 (USD million)
      4.2.3 Ceftazidime/Avibactum
              4.2.3.1 Global Ceftazidime/Avibactam Market Revenue, 2017 – 2020 (USD Million)
      4.2.4 Amikacin Inhale
              4.2.4.1 Global Amikacin Inhale Market Revenue, 2016 – 2020 (USD Million)
      4.2.5 Plazomicin
              4.2.5.1 Global Plazomicin Market Revenue, 2017 – 2020 (USD Million)
      4.2.6 Synflorix Vaccine
              4.2.6.1 Global Synflorix Market Revenue, 2012 – 2020 (USD Million)
4.3 Early Stage (Phase I and II)
      4.3.1 BAL30072
      4.3.2 MEDI4893
      4.3.3 AR-301 or KBSA301
      4.3.4 AR-101 (or KBPA101) and AR-104 (or KBPA104)
      4.3.5 AR-201 (or KBRV201)
      4.3.6 AR-401 (or KBAB401)
      4.3.7 ME1100
      4.3.8 GSK 2189242A
      4.3.9 V114
      4.3.10 IC43

Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography
5.1 Introduction
5.2 North America
5.3 Europe
5.4 Asia Pacific
5.5 Rest of the World

Chapter 6 Recommendations
6.1 Research and development for biological drugs
6.2 Mergers, acquisitions and strategic agreements

Chapter 7 Company Profiles
7.1 Achaogen, Inc.
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 Aridis Pharmaceuticals
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 AstraZeneca plc
      7.3.1 Company Profile
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Cubist Pharmaceuticals, Inc.
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
7.5 Meiji Seika Pharma Co. Ltd.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Merck & Co. Inc.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Sanofi
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
7.8 GlaxoSmithKline, Inc.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Product Portfolio
      7.8.4 Business Strategies
      7.8.5 Recent Developments
7.9 Valneva SE
      7.9.1 Company Overview
      7.9.2 Financial Overview
      7.9.3 Product Portfolio
      7.9.4 Business Strategies
      7.9.5 Recent Developments

List of Figures

FIG. 1 Hospital Acquired Pneumonia: Drug Pipeline
FIG. 2 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)
FIG. 3 Value Chain Analysis
FIG. 4 Porter’s Five Forces Analysis: Global Hospital Acquired Pneumonia Market
FIG. 5 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)
FIG. 6 Global Tedizolid Phosphate Market Revenue, 2017 – 2020 (USD Million)
FIG. 7 Global Ceftolozane/Tazobactam Market Revenue, 2017 – 2020 (USD million)
FIG. 8 Global Ceftazidime/Avibactam Market Revenue, 2017 – 2020 (USD Million)
FIG. 9 Global Amikacin Inhale Market Revenue, 2016 – 2020 (USD Million)
FIG. 10 Global Plazomicin Market Revenue, 2017 – 2020 (USD Million)
FIG. 11 Global Synflorix Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 AstraZeneca PLC: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 13 Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 14 Meiji Holdings, Co. Ltd., Pharmaceutical Segment.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 15 Merck & Co. Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 16 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 17 GlaxoSmithKline, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Nosocomial Pneumonia Drugs and Vaccines, Market Snapshot
TABLE 2 Investigational Candidates for Nosocomial Pneumonia Treatment
TABLE 3 Prevalence of Hospital Acquired Infections in Developed and Developing Countries
TABLE 4 Event Impact Analysis, Hospital Acquired Pneumonia Market

Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.

Phase III candidates include tedizolid phosphate, ceftolozane/tazobactam, ceftazidime/avibactam, amikacin inhale, plazomicin and synflorix vaccine. Market for each of the investigational drugs is estimated based on current anti-microbial efficiency, historic market trend and patents of drugs from similar class, manufacturing and marketing licenses, along with competition from commercialized and pipeline drugs. Hospital acquired pneumonia drugs market for phase III candidates has been estimated from the expected year of launch till 2020. The hospital acquired pneumonia drugs market report also gives a brief review of the various drugs commercially available for treating hospital acquired pneumonia. Historic market revenue of these drugs from 2011 to 2013 has also been included. Market forecast mainly rests on a detailed event impact analysis, which considers historic as well as anticipated events which impact the market in varying degrees. 

Global market for hospital acquired pneumonia drugs is mainly driven by the increasing prevalence of nosocomial infections across the globe. To illustrate this fact, the report includes a statistical comparison of the prevalence of nosocomial infections in various developed and developing countries. Geographical trend of hospital acquired pneumonia drugs market, is explains with a brief regulatory approval process, along with expected time frame for drug launch in various countries. These trends have been explained for geographical regions including North America, Europe, Asia Pacific and Rest of the World.

To gain a complete market understanding, Porters Five Force’s analysis, and value chain analysis has also been included in the hospital acquired pneumonia drugs market report. The report also explains key market drivers, restraints, opportunities in the hospital acquired pneumonia drugs market. Diagnosis, treatment, and epidemiology of hospital acquired pneumonia gives a clinical overview of the disease and current modes of disease management. Relevant recommendations have been suggested for designing successful market strategies for competing in the market. 

Hospital acquired pneumonia drugs market report also includes company profiles of key market players. These include Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Ltd., Sanofi, GlaxoSmithKline, Inc., and Valneva SE. All of these players are profiled considering company overview, financial overview, product portfolio, business strategies, and recent developments.   

The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed real time market scenario. This primary research represented the bulk of the research efforts, which was further supplemented by extensive secondary research. A review of key players’ product literature, annual reports, and press releases supports the market forecast analysis. The 74 page report explains various market dynamics in 4 tables and 17 figures and charts.


 
 
Back To Top